Back to all MindMaze Therapeutics Holding SA press releases
MindMaze Therapeutics Holding SA
- OTCQB:MMTZF
- SIX:MMTX
MindMaze Therapeutics completes NeuroX business combination
Published
At a glance
- Company
- MindMaze Therapeutics Holding SA
- Listings
- OTCQB:MMTZF, SIX:MMTX
- Announcement type
- Merger or acquisition
- Published
- Source announcement
- eqs-news.com
| Measure | Figure |
|---|---|
| Newly issued ordinary shares | 140,000,000 newly issued ordinary shares |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
MindMaze Therapeutics Holding SA (SIX: MMTX; OTCQB under RLFTF and RLFTY) completed its business combination with NeuroX Group SA; combined entity operates under that name.
- The closing followed a definitive business combination agreement signed in October 2025 and shareholder approval at November’s extraordinary general meeting.
- NeuroX was acquired through a share exchange: former shareholders contributed all outstanding shares for 140,000,000 newly issued ordinary shares.
- The new shares will be admitted to trading and listing on the SIX Swiss Exchange today, under the approved prospectus and applicable regulations.
- Effective immediately, all listed ordinary shares of the Company will trade under the updated ticker symbol MMTX.
Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.
Investor FAQs
Source announcement
- Company
- MindMaze Therapeutics Holding SA
- Title
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
- Published
- Source site
- eqs-news.com
Read the source announcement on eqs-news.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.